Guys, nobody cares about Bio-Tech atm, regardless of the value and assets.
IMU goes from strength to strength on the medical front and gets shot down further almost every day. RAD is another extreme, for $ 65m a buyer would get still at least $70m in cash, a 75% stake in a JV with one of the world's biggest Cancer Centers, MD Anderson Texas, royalty streams on 2 assets developed by giant Lantheus and 4 more world leading assets with 1 already in the clinic.
That's how crazy things have become and yes, ALA having not even an IND for a trial is worth $150m.
To amend a well know phrase, " The market can stay longer irrational than we might think ", but with enough stamina we could make a huge fortune.
Hard to tell what comes first, 1c or 2c. All depends on the CR, the next GBM read isn't due before March '25 and the other fronts won't deliver anything exciting before end '25. IMU's Azer-Cel delivered 3 complete responses among patients on death row and apart of a one-day spike the sp has fallen well below that anns. That way any interim update on CDH17 won't help much.
Only one way to make a buck with CHM in the foreseeable future is via an all cash t/o. Anything else won't work as there are too many idiots selling everything down in the first second after any anns. IMU and RAD are the best current examples for that, next to CHM.
GLTA
CHM Price at posting:
1.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)